Stay updated with breaking news from Key Updates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.
Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.
Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.
Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.
A panel of medical oncologist reflect on clinical data from the ARASENS and ARANOTE trials utilizing combination strategies with darolutamide in mHSPC.